Citigroup’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q1 | – | Sell |
-582
| Closed | – | – | 8046 |
|
|
2018
Q4 | $0 | Hold |
582
| – | – | ﹤0.01% | 8066 |
|
|
2018
Q3 | $1K | Sell |
582
-50
| -8% | -$78 | ﹤0.01% | 7714 |
|
|
2018
Q2 | $1K | Sell |
632
-3,792
| -86% | -$5.81K | ﹤0.01% | 7575 |
|
|
2018
Q1 | $7K | Buy |
4,424
+846
| +24% | +$1.77K | ﹤0.01% | 7155 |
|
|
2017
Q4 | $8K | Buy |
3,578
+2,907
| +433% | +$7.36K | ﹤0.01% | 7137 |
|
|
2017
Q3 | $2K | Sell |
671
-89
| -12% | -$299 | ﹤0.01% | 7087 |
|
|
2017
Q2 | $3K | Sell |
760
-50
| -6% | -$165 | ﹤0.01% | 6953 |
|
|
2017
Q1 | $3K | Sell |
810
-22,599
| -97% | -$87.9K | ﹤0.01% | 6978 |
|
|
2016
Q4 | $108K | Buy |
23,409
+20,966
| +858% | +$86.5K | ﹤0.01% | 5730 |
|
|
2016
Q3 | $10K | Sell |
2,443
-425
| -15% | -$1.38K | ﹤0.01% | 6560 |
|
|
2016
Q2 | $6K | Sell |
2,868
-7,501
| -72% | -$27.1K | ﹤0.01% | 6752 |
|
|
2016
Q1 | $48K | Buy |
10,369
+5,527
| +114% | +$21.4K | ﹤0.01% | 6140 |
|
|
2015
Q4 | $19K | Buy |
4,842
+3,158
| +188% | +$14.6K | ﹤0.01% | 6519 |
|
|
2015
Q3 | $7K | Sell |
1,684
-23,302
| -93% | -$107K | ﹤0.01% | 6627 |
|
|
2015
Q2 | $114K | Buy |
24,986
+24,160
| +2,925% | +$232K | ﹤0.01% | 4896 |
|
|
2015
Q1 | $6K | Buy |
826
+74
| +10% | +$366 | ﹤0.01% | 6691 |
|
|
2014
Q4 | $2K | Buy |
+752
| New | +$3.03K | ﹤0.01% | 6928 |
|
Citigroup's AST Position: Q1 2019 in Review
Citigroup sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q1 2019, closing a stake of 582 shares.
Citigroup first reported a position in AST in Q4 2014 and held it in 17 quarters. The position peaked at $114K in Q2 2015. 0 funds tracked by Wall St. Rank hold AST as of Q1 2019.
- Citigroup reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q1 2019 after selling out during the quarter.
- Citigroup sold 582 Asterias Biotherapeutics Inc. Series A shares in Q1 2019.
- Citigroup first reported a position in Asterias Biotherapeutics Inc. Series A in Q4 2014 and held it in 17 quarters.
- Citigroup's Asterias Biotherapeutics Inc. Series A position peaked at $114K in Q2 2015.
- 0 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q1 2019.
Based on Citigroup's 13F filing for Q1 2019, filed 13 May 2019.